MedinCell S.A.

MEDCL · Euronext Paris

MedinCell S.A. (MEDCL) is a Biotechnology company in the Healthcare sector, listed on Euronext Paris. This page provides the complete earnings calendar, dividend schedule, and financial data for MedinCell S.A. in 2026. The next earnings report is expected on December 8, 2026.

Earnings calendar

Next earnings date

08 Dec 2026

In 109 days

EPS estimate

-0.27

Revenue estimate

19.0M

Past earnings

Date	EPS actual	Revenue actual	1d	5d	30d
16 Jun 2026	-0.52 (-221.4%) estimate -0.16	11.7M (-37.3%) estimate 18.6M	+2.37%	-2.41%	+4.37%

16 Jun 2026

EPS actual

-0.52 (-221.4%)

estimate -0.16

Revenue actual

11.7M (-37.3%)

estimate 18.6M

Price reaction

+2.37%

-2.41%

30d

+4.37%

Beat Miss usd

Latest earnings analysis

MedinCell S.A. missed consensus estimates in its latest earnings report, with EPS of USD -0.5199 versus an estimate of USD -0.1618 and revenue of USD 11.67 million, 37.3% below estimates. There is no prior report available for comparison.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.

Sector: Healthcare
Industry: Biotechnology
Country: France
Exchange: Euronext Paris
CEO: Christophe Douat
Employees: 140
IPO date: 08 Oct 2018
ISIN: FR0004065605
Website: medincell.com

Frequently asked questions

When does MedinCell S.A. (MEDCL) next report earnings?

MedinCell S.A. (MEDCL) is scheduled to report earnings on December 8, 2026.

What was MedinCell S.A.'s most recent earnings date?

MedinCell S.A. (MEDCL) last reported earnings on June 16, 2026.

Where is MedinCell S.A. stock listed?

MedinCell S.A. (MEDCL) is listed on Euronext Paris.